Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Dimopoulos, Meletios, MD, Siegel, David S, MD, Lonial, Sagar, MD, Qi, Junyuan, MD, Hajek, Roman, MD, Facon, Thierry, MD, Rosinol, Laura, MD, Williams, Catherine, MD, Blacklock, Hilary, MD, Goldschmidt, Hartmut, MD, Hungria, Vania, MD, Spencer, Andrew, MD, Palumbo, Antonio, MD, Graef, Thorsten, MD, Eid, Joseph E, MD, Houp, Jennifer, PharmD, Sun, Linda, PhD, Vuocolo, Scott, PhD, Anderson, Kenneth C, MD
Published in The lancet oncology (01.10.2013)
Published in The lancet oncology (01.10.2013)
Get full text
Journal Article